Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Bone malformations in interleukin-18 transgenic mice.

Kawase Y, Hoshino T, Yokota K, Kuzuhara A, Nakamura M, Maeda Y, Nishiwaki E, Zenmyo M, Hiraoka K, Aizawa H, Yoshino K.

J Bone Miner Res. 2003 Jun;18(6):975-83.

2.

Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.

Wang L, Liu S, Quarles LD, Spurney RF.

Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E826-34. Epub 2004 Dec 7.

PMID:
15585587
3.
4.

Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).

Wang L, Quarles LD, Spurney RF.

J Bone Miner Res. 2004 Oct;19(10):1661-70. Epub 2004 Jul 14.

5.

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.

Blood. 2002 Dec 15;100(13):4615-21. Epub 2002 Aug 8.

6.

Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis.

Onodera S, Sasaki S, Ohshima S, Amizuka N, Li M, Udagawa N, Irie K, Nishihira J, Koyama Y, Shiraishi A, Tohyama H, Yasuda K.

J Bone Miner Res. 2006 Jun;21(6):876-85.

7.

Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice.

Sakai A, Mori T, Sakuma-Zenke M, Takeda T, Nakai K, Katae Y, Hirasawa H, Nakamura T.

J Bone Miner Metab. 2005;23(1):8-14.

PMID:
15616888
9.

IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.

Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB.

J Immunol. 2003 Mar 1;170(5):2655-62.

10.

Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.

Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.

Bone. 2005 Jan;36(1):159-72. Epub 2004 Nov 24.

PMID:
15664014
11.

Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells.

Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, Yamada N, Sugihara A, Okamura H, Hayashi S, Terada N.

Biochem Biophys Res Commun. 2001 Feb 23;281(2):361-6.

PMID:
11181055
12.

T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis.

Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT.

J Bone Miner Res. 2003 Jun;18(6):984-93.

13.

Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss.

Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA.

J Bone Miner Res. 2006 May;21(5):695-702.

15.

Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation.

Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT.

J Exp Med. 1997 Mar 17;185(6):1005-12.

18.

Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.

Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, Lacey DL.

J Orthop Res. 2000 Nov;18(6):967-76.

PMID:
11192258
19.

Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.

Dohlsten M, Björklund M, Sundstedt A, Hedlund G, Samson D, Kalland T.

Immunology. 1993 Aug;79(4):520-7.

Supplemental Content

Support Center